MedTrace Logo

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment

NCT03644511 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2020-08-21

No results posted yet for this study

Summary

Researchers already did trials that showed Sorafenib and Regorafenib worked for patients with hepatocellular carcinoma (most common liver tumor type).

In this trial, they want to learn more about the same patient group in which Sorafenib or Regorafenib is given after other drugs. Patients participating in this study will be observed until 12 months after the last patient has been enrolled to collect data on how safe the drugs are and how well they are working when used as second line or beyond treatment.

Conditions

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

Prescribed by physician.

DRUG

Sorafenib (Nexavar, BAY43-9006)

Prescribed by physician.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-24
Primary Completion
2019-07-18
Completion
2019-09-30

Countries

  • Germany

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03644511 on ClinicalTrials.gov